ONIRIA THERAPEUTICS, S.L.

Oniria Therapeutics is a biopharmaceutical company focused on precision oncology and addressing cancer persistence and recurrence. Its lead candidate, ONR-001, is entering regulatory preclinical development and has shown strong in vivo efficacy in colorectal cancer, melanoma, and acute myeloid leukemia, as well as in vitro activity in additional indications. Acute and sub-chronic safety have been demonstrated in rodents, and acute safety has been confirmed in non-rodents.